A 12 week, multi-center, double-blind, randomized, parallel group study, followed by a 12 month extension study, of the efficacy and safety of LCP-atorFen in subjects with dyslipidemia
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Atorvastatin; Atorvastatin/fenofibrate; Fenofibrate
- Indications Dyslipidaemias
- Focus Therapeutic Use
- 24 Mar 2020 Biomarkers information updated
- 10 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 10 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.